nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—CYP3A5—Teniposide—lymphatic system cancer	0.159	0.271	CbGbCtD
Boceprevir—CYP3A5—Vincristine—lymphatic system cancer	0.0767	0.131	CbGbCtD
Boceprevir—ABCB1—Mitoxantrone—lymphatic system cancer	0.0726	0.123	CbGbCtD
Boceprevir—CYP3A4—Cytarabine—lymphatic system cancer	0.0631	0.107	CbGbCtD
Boceprevir—CYP3A4—Teniposide—lymphatic system cancer	0.0622	0.106	CbGbCtD
Boceprevir—ABCB1—Vincristine—lymphatic system cancer	0.0499	0.085	CbGbCtD
Boceprevir—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0435	0.074	CbGbCtD
Boceprevir—ABCB1—Methotrexate—lymphatic system cancer	0.0302	0.0515	CbGbCtD
Boceprevir—CYP3A4—Vincristine—lymphatic system cancer	0.0299	0.0509	CbGbCtD
Boceprevir—Alopecia—Carmustine—lymphatic system cancer	0.000663	0.00161	CcSEcCtD
Boceprevir—Body temperature increased—Fludarabine—lymphatic system cancer	0.000658	0.0016	CcSEcCtD
Boceprevir—Mental disorder—Carmustine—lymphatic system cancer	0.000657	0.00159	CcSEcCtD
Boceprevir—Malnutrition—Carmustine—lymphatic system cancer	0.000653	0.00158	CcSEcCtD
Boceprevir—Erythema—Carmustine—lymphatic system cancer	0.000653	0.00158	CcSEcCtD
Boceprevir—Cough—Bleomycin—lymphatic system cancer	0.000652	0.00158	CcSEcCtD
Boceprevir—Angiopathy—Vincristine—lymphatic system cancer	0.000649	0.00157	CcSEcCtD
Boceprevir—Diarrhoea—Teniposide—lymphatic system cancer	0.000648	0.00157	CcSEcCtD
Boceprevir—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000645	0.00156	CcSEcCtD
Boceprevir—Chest pain—Bleomycin—lymphatic system cancer	0.000637	0.00154	CcSEcCtD
Boceprevir—Myalgia—Bleomycin—lymphatic system cancer	0.000637	0.00154	CcSEcCtD
Boceprevir—Alopecia—Vincristine—lymphatic system cancer	0.000632	0.00153	CcSEcCtD
Boceprevir—Back pain—Carmustine—lymphatic system cancer	0.000631	0.00153	CcSEcCtD
Boceprevir—Discomfort—Bleomycin—lymphatic system cancer	0.000629	0.00152	CcSEcCtD
Boceprevir—Mental disorder—Vincristine—lymphatic system cancer	0.000627	0.00152	CcSEcCtD
Boceprevir—Chills—Mitoxantrone—lymphatic system cancer	0.000625	0.00152	CcSEcCtD
Boceprevir—Neoplasm—Methotrexate—lymphatic system cancer	0.000625	0.00152	CcSEcCtD
Boceprevir—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000625	0.00152	CcSEcCtD
Boceprevir—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000623	0.00151	CcSEcCtD
Boceprevir—Alopecia—Mitoxantrone—lymphatic system cancer	0.000616	0.00149	CcSEcCtD
Boceprevir—Confusional state—Bleomycin—lymphatic system cancer	0.000615	0.00149	CcSEcCtD
Boceprevir—Vision blurred—Carmustine—lymphatic system cancer	0.000615	0.00149	CcSEcCtD
Boceprevir—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000613	0.00149	CcSEcCtD
Boceprevir—Erythema—Mitoxantrone—lymphatic system cancer	0.000607	0.00147	CcSEcCtD
Boceprevir—Infection—Bleomycin—lymphatic system cancer	0.000606	0.00147	CcSEcCtD
Boceprevir—Anaemia—Carmustine—lymphatic system cancer	0.000603	0.00146	CcSEcCtD
Boceprevir—Back pain—Vincristine—lymphatic system cancer	0.000603	0.00146	CcSEcCtD
Boceprevir—Vomiting—Teniposide—lymphatic system cancer	0.000602	0.00146	CcSEcCtD
Boceprevir—Sepsis—Methotrexate—lymphatic system cancer	0.0006	0.00145	CcSEcCtD
Boceprevir—Agitation—Carmustine—lymphatic system cancer	0.0006	0.00145	CcSEcCtD
Boceprevir—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000597	0.00145	CcSEcCtD
Boceprevir—Asthenia—Fludarabine—lymphatic system cancer	0.000597	0.00145	CcSEcCtD
Boceprevir—Rash—Teniposide—lymphatic system cancer	0.000597	0.00145	CcSEcCtD
Boceprevir—Dermatitis—Teniposide—lymphatic system cancer	0.000597	0.00145	CcSEcCtD
Boceprevir—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000594	0.00144	CcSEcCtD
Boceprevir—Headache—Teniposide—lymphatic system cancer	0.000593	0.00144	CcSEcCtD
Boceprevir—Pruritus—Fludarabine—lymphatic system cancer	0.000589	0.00143	CcSEcCtD
Boceprevir—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000588	0.00143	CcSEcCtD
Boceprevir—Back pain—Mitoxantrone—lymphatic system cancer	0.000587	0.00142	CcSEcCtD
Boceprevir—Leukopenia—Carmustine—lymphatic system cancer	0.000584	0.00142	CcSEcCtD
Boceprevir—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000577	0.0014	CcSEcCtD
Boceprevir—Anaemia—Vincristine—lymphatic system cancer	0.000576	0.0014	CcSEcCtD
Boceprevir—Agitation—Vincristine—lymphatic system cancer	0.000573	0.00139	CcSEcCtD
Boceprevir—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000572	0.00139	CcSEcCtD
Boceprevir—Hypotension—Bleomycin—lymphatic system cancer	0.00057	0.00138	CcSEcCtD
Boceprevir—Diarrhoea—Fludarabine—lymphatic system cancer	0.000569	0.00138	CcSEcCtD
Boceprevir—Hypertension—Carmustine—lymphatic system cancer	0.000563	0.00137	CcSEcCtD
Boceprevir—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000563	0.00136	CcSEcCtD
Boceprevir—Nausea—Teniposide—lymphatic system cancer	0.000562	0.00136	CcSEcCtD
Boceprevir—Anaemia—Mitoxantrone—lymphatic system cancer	0.000561	0.00136	CcSEcCtD
Boceprevir—Vertigo—Vincristine—lymphatic system cancer	0.00056	0.00136	CcSEcCtD
Boceprevir—Leukopenia—Vincristine—lymphatic system cancer	0.000558	0.00135	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000556	0.00135	CcSEcCtD
Boceprevir—Myalgia—Carmustine—lymphatic system cancer	0.000556	0.00135	CcSEcCtD
Boceprevir—Chest pain—Carmustine—lymphatic system cancer	0.000556	0.00135	CcSEcCtD
Boceprevir—Anxiety—Carmustine—lymphatic system cancer	0.000554	0.00134	CcSEcCtD
Boceprevir—Paraesthesia—Bleomycin—lymphatic system cancer	0.000548	0.00133	CcSEcCtD
Boceprevir—Malaise—Mitoxantrone—lymphatic system cancer	0.000547	0.00133	CcSEcCtD
Boceprevir—Dyspnoea—Bleomycin—lymphatic system cancer	0.000544	0.00132	CcSEcCtD
Boceprevir—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000543	0.00132	CcSEcCtD
Boceprevir—Hypertension—Vincristine—lymphatic system cancer	0.000538	0.0013	CcSEcCtD
Boceprevir—Confusional state—Carmustine—lymphatic system cancer	0.000537	0.0013	CcSEcCtD
Boceprevir—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000532	0.00129	CcSEcCtD
Boceprevir—Decreased appetite—Bleomycin—lymphatic system cancer	0.00053	0.00129	CcSEcCtD
Boceprevir—Myalgia—Vincristine—lymphatic system cancer	0.00053	0.00129	CcSEcCtD
Boceprevir—Cough—Mitoxantrone—lymphatic system cancer	0.000529	0.00128	CcSEcCtD
Boceprevir—Infection—Carmustine—lymphatic system cancer	0.000529	0.00128	CcSEcCtD
Boceprevir—Vomiting—Fludarabine—lymphatic system cancer	0.000529	0.00128	CcSEcCtD
Boceprevir—Rash—Fludarabine—lymphatic system cancer	0.000525	0.00127	CcSEcCtD
Boceprevir—Dermatitis—Fludarabine—lymphatic system cancer	0.000524	0.00127	CcSEcCtD
Boceprevir—Hypertension—Mitoxantrone—lymphatic system cancer	0.000524	0.00127	CcSEcCtD
Boceprevir—Pain—Bleomycin—lymphatic system cancer	0.000522	0.00127	CcSEcCtD
Boceprevir—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000522	0.00126	CcSEcCtD
Boceprevir—Headache—Fludarabine—lymphatic system cancer	0.000521	0.00126	CcSEcCtD
Boceprevir—Tachycardia—Carmustine—lymphatic system cancer	0.00052	0.00126	CcSEcCtD
Boceprevir—Chest pain—Mitoxantrone—lymphatic system cancer	0.000517	0.00125	CcSEcCtD
Boceprevir—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000517	0.00125	CcSEcCtD
Boceprevir—Myalgia—Mitoxantrone—lymphatic system cancer	0.000517	0.00125	CcSEcCtD
Boceprevir—Anxiety—Mitoxantrone—lymphatic system cancer	0.000515	0.00125	CcSEcCtD
Boceprevir—Lethargy—Methotrexate—lymphatic system cancer	0.000512	0.00124	CcSEcCtD
Boceprevir—Discomfort—Mitoxantrone—lymphatic system cancer	0.00051	0.00124	CcSEcCtD
Boceprevir—Infection—Vincristine—lymphatic system cancer	0.000505	0.00122	CcSEcCtD
Boceprevir—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000503	0.00122	CcSEcCtD
Boceprevir—Confusional state—Mitoxantrone—lymphatic system cancer	0.000499	0.00121	CcSEcCtD
Boceprevir—Nervous system disorder—Vincristine—lymphatic system cancer	0.000499	0.00121	CcSEcCtD
Boceprevir—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000498	0.00121	CcSEcCtD
Boceprevir—Hypotension—Carmustine—lymphatic system cancer	0.000498	0.00121	CcSEcCtD
Boceprevir—Nausea—Fludarabine—lymphatic system cancer	0.000494	0.0012	CcSEcCtD
Boceprevir—Infection—Mitoxantrone—lymphatic system cancer	0.000492	0.00119	CcSEcCtD
Boceprevir—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000492	0.00119	CcSEcCtD
Boceprevir—Shock—Mitoxantrone—lymphatic system cancer	0.000487	0.00118	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000485	0.00118	CcSEcCtD
Boceprevir—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000485	0.00118	CcSEcCtD
Boceprevir—Urticaria—Bleomycin—lymphatic system cancer	0.000485	0.00118	CcSEcCtD
Boceprevir—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000483	0.00117	CcSEcCtD
Boceprevir—Body temperature increased—Bleomycin—lymphatic system cancer	0.000482	0.00117	CcSEcCtD
Boceprevir—Insomnia—Carmustine—lymphatic system cancer	0.000482	0.00117	CcSEcCtD
Boceprevir—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000481	0.00117	CcSEcCtD
Boceprevir—Irritability—Methotrexate—lymphatic system cancer	0.000479	0.00116	CcSEcCtD
Boceprevir—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000479	0.00116	CcSEcCtD
Boceprevir—Paraesthesia—Carmustine—lymphatic system cancer	0.000478	0.00116	CcSEcCtD
Boceprevir—Mood swings—Methotrexate—lymphatic system cancer	0.000476	0.00115	CcSEcCtD
Boceprevir—Hypotension—Vincristine—lymphatic system cancer	0.000475	0.00115	CcSEcCtD
Boceprevir—Dyspnoea—Carmustine—lymphatic system cancer	0.000475	0.00115	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000463	0.00112	CcSEcCtD
Boceprevir—Decreased appetite—Carmustine—lymphatic system cancer	0.000463	0.00112	CcSEcCtD
Boceprevir—Hypotension—Mitoxantrone—lymphatic system cancer	0.000463	0.00112	CcSEcCtD
Boceprevir—Insomnia—Vincristine—lymphatic system cancer	0.00046	0.00111	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00046	0.00111	CcSEcCtD
Boceprevir—Paraesthesia—Vincristine—lymphatic system cancer	0.000457	0.00111	CcSEcCtD
Boceprevir—Constipation—Carmustine—lymphatic system cancer	0.000455	0.0011	CcSEcCtD
Boceprevir—Pain—Carmustine—lymphatic system cancer	0.000455	0.0011	CcSEcCtD
Boceprevir—Breast disorder—Methotrexate—lymphatic system cancer	0.000454	0.0011	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000451	0.00109	CcSEcCtD
Boceprevir—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00045	0.00109	CcSEcCtD
Boceprevir—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000445	0.00108	CcSEcCtD
Boceprevir—Decreased appetite—Vincristine—lymphatic system cancer	0.000442	0.00107	CcSEcCtD
Boceprevir—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000441	0.00107	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000439	0.00106	CcSEcCtD
Boceprevir—Feeling abnormal—Carmustine—lymphatic system cancer	0.000439	0.00106	CcSEcCtD
Boceprevir—Fatigue—Vincristine—lymphatic system cancer	0.000438	0.00106	CcSEcCtD
Boceprevir—Asthenia—Bleomycin—lymphatic system cancer	0.000438	0.00106	CcSEcCtD
Boceprevir—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000436	0.00106	CcSEcCtD
Boceprevir—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000436	0.00106	CcSEcCtD
Boceprevir—Pain—Vincristine—lymphatic system cancer	0.000435	0.00105	CcSEcCtD
Boceprevir—Constipation—Vincristine—lymphatic system cancer	0.000435	0.00105	CcSEcCtD
Boceprevir—Pruritus—Bleomycin—lymphatic system cancer	0.000432	0.00105	CcSEcCtD
Boceprevir—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00043	0.00104	CcSEcCtD
Boceprevir—Eosinophilia—Methotrexate—lymphatic system cancer	0.00043	0.00104	CcSEcCtD
Boceprevir—Fatigue—Mitoxantrone—lymphatic system cancer	0.000427	0.00104	CcSEcCtD
Boceprevir—Pancreatitis—Methotrexate—lymphatic system cancer	0.000425	0.00103	CcSEcCtD
Boceprevir—Constipation—Mitoxantrone—lymphatic system cancer	0.000423	0.00103	CcSEcCtD
Boceprevir—Pain—Mitoxantrone—lymphatic system cancer	0.000423	0.00103	CcSEcCtD
Boceprevir—Body temperature increased—Carmustine—lymphatic system cancer	0.000421	0.00102	CcSEcCtD
Boceprevir—Abdominal pain—Carmustine—lymphatic system cancer	0.000421	0.00102	CcSEcCtD
Boceprevir—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000416	0.00101	CcSEcCtD
Boceprevir—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000416	0.00101	CcSEcCtD
Boceprevir—Pancytopenia—Methotrexate—lymphatic system cancer	0.000412	0.000999	CcSEcCtD
Boceprevir—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000408	0.000989	CcSEcCtD
Boceprevir—Dysuria—Methotrexate—lymphatic system cancer	0.000406	0.000984	CcSEcCtD
Boceprevir—Neutropenia—Methotrexate—lymphatic system cancer	0.000406	0.000984	CcSEcCtD
Boceprevir—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000405	0.000982	CcSEcCtD
Boceprevir—Abdominal pain—Vincristine—lymphatic system cancer	0.000402	0.000974	CcSEcCtD
Boceprevir—Body temperature increased—Vincristine—lymphatic system cancer	0.000402	0.000974	CcSEcCtD
Boceprevir—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.0004	0.000969	CcSEcCtD
Boceprevir—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000396	0.00096	CcSEcCtD
Boceprevir—Urticaria—Mitoxantrone—lymphatic system cancer	0.000393	0.000954	CcSEcCtD
Boceprevir—Hypersensitivity—Carmustine—lymphatic system cancer	0.000392	0.000951	CcSEcCtD
Boceprevir—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000391	0.000949	CcSEcCtD
Boceprevir—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000391	0.000949	CcSEcCtD
Boceprevir—Pneumonia—Methotrexate—lymphatic system cancer	0.000389	0.000943	CcSEcCtD
Boceprevir—Vomiting—Bleomycin—lymphatic system cancer	0.000388	0.000941	CcSEcCtD
Boceprevir—Infestation NOS—Methotrexate—lymphatic system cancer	0.000387	0.000938	CcSEcCtD
Boceprevir—Infestation—Methotrexate—lymphatic system cancer	0.000387	0.000938	CcSEcCtD
Boceprevir—Depression—Methotrexate—lymphatic system cancer	0.000386	0.000935	CcSEcCtD
Boceprevir—Rash—Bleomycin—lymphatic system cancer	0.000385	0.000933	CcSEcCtD
Boceprevir—Dermatitis—Bleomycin—lymphatic system cancer	0.000384	0.000932	CcSEcCtD
Boceprevir—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000384	0.00093	CcSEcCtD
Boceprevir—Asthenia—Carmustine—lymphatic system cancer	0.000382	0.000927	CcSEcCtD
Boceprevir—Stomatitis—Methotrexate—lymphatic system cancer	0.000377	0.000914	CcSEcCtD
Boceprevir—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000376	0.000912	CcSEcCtD
Boceprevir—Hypersensitivity—Vincristine—lymphatic system cancer	0.000375	0.000908	CcSEcCtD
Boceprevir—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000366	0.000887	CcSEcCtD
Boceprevir—Epistaxis—Methotrexate—lymphatic system cancer	0.000365	0.000885	CcSEcCtD
Boceprevir—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000365	0.000884	CcSEcCtD
Boceprevir—Asthenia—Vincristine—lymphatic system cancer	0.000365	0.000884	CcSEcCtD
Boceprevir—Diarrhoea—Carmustine—lymphatic system cancer	0.000364	0.000884	CcSEcCtD
Boceprevir—Nausea—Bleomycin—lymphatic system cancer	0.000362	0.000879	CcSEcCtD
Boceprevir—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000361	0.000875	CcSEcCtD
Boceprevir—Asthenia—Mitoxantrone—lymphatic system cancer	0.000355	0.000861	CcSEcCtD
Boceprevir—Dizziness—Carmustine—lymphatic system cancer	0.000352	0.000854	CcSEcCtD
Boceprevir—Diarrhoea—Vincristine—lymphatic system cancer	0.000348	0.000843	CcSEcCtD
Boceprevir—Pharyngitis—Methotrexate—lymphatic system cancer	0.000345	0.000836	CcSEcCtD
Boceprevir—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000343	0.000831	CcSEcCtD
Boceprevir—Urethral disorder—Methotrexate—lymphatic system cancer	0.00034	0.000825	CcSEcCtD
Boceprevir—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000339	0.000821	CcSEcCtD
Boceprevir—Vomiting—Carmustine—lymphatic system cancer	0.000339	0.000821	CcSEcCtD
Boceprevir—Dizziness—Vincristine—lymphatic system cancer	0.000336	0.000815	CcSEcCtD
Boceprevir—Rash—Carmustine—lymphatic system cancer	0.000336	0.000814	CcSEcCtD
Boceprevir—Dermatitis—Carmustine—lymphatic system cancer	0.000336	0.000813	CcSEcCtD
Boceprevir—Visual impairment—Methotrexate—lymphatic system cancer	0.000335	0.000811	CcSEcCtD
Boceprevir—Headache—Carmustine—lymphatic system cancer	0.000334	0.000809	CcSEcCtD
Boceprevir—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000328	0.000796	CcSEcCtD
Boceprevir—Eye disorder—Methotrexate—lymphatic system cancer	0.000325	0.000787	CcSEcCtD
Boceprevir—Tinnitus—Methotrexate—lymphatic system cancer	0.000324	0.000785	CcSEcCtD
Boceprevir—Vomiting—Vincristine—lymphatic system cancer	0.000323	0.000784	CcSEcCtD
Boceprevir—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000322	0.000781	CcSEcCtD
Boceprevir—Rash—Vincristine—lymphatic system cancer	0.000321	0.000777	CcSEcCtD
Boceprevir—Dermatitis—Vincristine—lymphatic system cancer	0.00032	0.000777	CcSEcCtD
Boceprevir—Headache—Vincristine—lymphatic system cancer	0.000319	0.000772	CcSEcCtD
Boceprevir—Nausea—Carmustine—lymphatic system cancer	0.000316	0.000767	CcSEcCtD
Boceprevir—Angiopathy—Methotrexate—lymphatic system cancer	0.000315	0.000764	CcSEcCtD
Boceprevir—Vomiting—Mitoxantrone—lymphatic system cancer	0.000315	0.000763	CcSEcCtD
Boceprevir—Immune system disorder—Methotrexate—lymphatic system cancer	0.000314	0.00076	CcSEcCtD
Boceprevir—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000313	0.000759	CcSEcCtD
Boceprevir—Rash—Mitoxantrone—lymphatic system cancer	0.000312	0.000757	CcSEcCtD
Boceprevir—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000312	0.000756	CcSEcCtD
Boceprevir—Chills—Methotrexate—lymphatic system cancer	0.000312	0.000755	CcSEcCtD
Boceprevir—Headache—Mitoxantrone—lymphatic system cancer	0.00031	0.000752	CcSEcCtD
Boceprevir—Alopecia—Methotrexate—lymphatic system cancer	0.000307	0.000744	CcSEcCtD
Boceprevir—Mental disorder—Methotrexate—lymphatic system cancer	0.000304	0.000738	CcSEcCtD
Boceprevir—Erythema—Methotrexate—lymphatic system cancer	0.000302	0.000733	CcSEcCtD
Boceprevir—Malnutrition—Methotrexate—lymphatic system cancer	0.000302	0.000733	CcSEcCtD
Boceprevir—Nausea—Vincristine—lymphatic system cancer	0.000302	0.000732	CcSEcCtD
Boceprevir—Dysgeusia—Methotrexate—lymphatic system cancer	0.000296	0.000718	CcSEcCtD
Boceprevir—Nausea—Mitoxantrone—lymphatic system cancer	0.000294	0.000713	CcSEcCtD
Boceprevir—Back pain—Methotrexate—lymphatic system cancer	0.000292	0.000709	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—lymphatic system cancer	0.000285	0.000691	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00028	0.00068	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—lymphatic system cancer	0.000279	0.000677	CcSEcCtD
Boceprevir—Malaise—Methotrexate—lymphatic system cancer	0.000273	0.000661	CcSEcCtD
Boceprevir—Vertigo—Methotrexate—lymphatic system cancer	0.000272	0.000658	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—lymphatic system cancer	0.000271	0.000656	CcSEcCtD
Boceprevir—Cough—Methotrexate—lymphatic system cancer	0.000264	0.00064	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—lymphatic system cancer	0.000257	0.000624	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—lymphatic system cancer	0.000257	0.000624	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—lymphatic system cancer	0.000257	0.000624	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000256	0.00062	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—lymphatic system cancer	0.000254	0.000616	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—lymphatic system cancer	0.000249	0.000603	CcSEcCtD
Boceprevir—Infection—Methotrexate—lymphatic system cancer	0.000245	0.000594	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000242	0.000587	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000242	0.000586	CcSEcCtD
Boceprevir—Skin disorder—Methotrexate—lymphatic system cancer	0.00024	0.000581	CcSEcCtD
Boceprevir—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000239	0.000578	CcSEcCtD
Boceprevir—Hypotension—Methotrexate—lymphatic system cancer	0.000231	0.000559	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000225	0.000545	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—lymphatic system cancer	0.000223	0.000541	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—lymphatic system cancer	0.000222	0.000537	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—lymphatic system cancer	0.00022	0.000533	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—lymphatic system cancer	0.000217	0.000527	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—lymphatic system cancer	0.000214	0.00052	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000213	0.000516	CcSEcCtD
Boceprevir—Fatigue—Methotrexate—lymphatic system cancer	0.000213	0.000516	CcSEcCtD
Boceprevir—Pain—Methotrexate—lymphatic system cancer	0.000211	0.000511	CcSEcCtD
Boceprevir—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000203	0.000493	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000202	0.000489	CcSEcCtD
Boceprevir—Urticaria—Methotrexate—lymphatic system cancer	0.000196	0.000475	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—lymphatic system cancer	0.000195	0.000473	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—lymphatic system cancer	0.000195	0.000473	CcSEcCtD
Boceprevir—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000182	0.000441	CcSEcCtD
Boceprevir—Asthenia—Methotrexate—lymphatic system cancer	0.000177	0.000429	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—lymphatic system cancer	0.000175	0.000423	CcSEcCtD
Boceprevir—Diarrhoea—Methotrexate—lymphatic system cancer	0.000169	0.000409	CcSEcCtD
Boceprevir—Dizziness—Methotrexate—lymphatic system cancer	0.000163	0.000396	CcSEcCtD
Boceprevir—Vomiting—Methotrexate—lymphatic system cancer	0.000157	0.00038	CcSEcCtD
Boceprevir—Rash—Methotrexate—lymphatic system cancer	0.000156	0.000377	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—lymphatic system cancer	0.000155	0.000377	CcSEcCtD
Boceprevir—Headache—Methotrexate—lymphatic system cancer	0.000155	0.000375	CcSEcCtD
Boceprevir—Nausea—Methotrexate—lymphatic system cancer	0.000147	0.000355	CcSEcCtD
